The amyloid cascade hypothesis, according to which the self-assembly of amyloid-β peptide (Aβ) is a causative process in Alzheimer's disease, has driven many therapeutic efforts for the past 20 years. Failures of clinical trials investigating Aβ-targeted therapies have been interpreted as evidence against this hypothesis, irrespective of the characteristics and mechanisms of action of the therapeutic agents, which are highly challenging to assess. We bring together kinetic analysis with quantitative binding measurements to address the mechanisms of action of four clinical stage anti-Aβ antibodies, aducanumab, gantenerumab, bapineuzumab and solanezumab. We reveal and quantify the striking differences of these antibodies on the aggregation kinetics and on the production of oligomeric aggregates, and link these effects to the affinity and stoichiometry of each antibody for monomeric and fibrillar forms of Aβ. Our results uncover that, uniquely amongst these four antibodies, aducanumab dramatically reduces the flux of oligomeric forms of Aβ.
Alzheimer's disease affects nearly 50 million people worldwide with an overall cost corresponding to more than 1% of the global economy. The amyloid hypothesis (1, 2) has motivated the development of many therapeutic antibodies targeting different species of the Aβ peptide, with most of these immunotherapeutic approaches focusing on achieving a global reduction in the concentration of Aβ aggregates or a corresponding delay in the overall Aβ aggregation rate (3) . Increasing evidence, however, indicates that different Aβ aggregates may have different pathological effects (4, 5) . In particular, biophysical, cellular and histological data have highlighted a more pronounced toxicity of oligomeric intermediates of lower molecular weight, relative to that of large fibrillar species. It is therefore critical to determine the effects of potential anti-Aβ therapeutics on the underlying microscopic steps of Aβ aggregation (5, 6) , since many overall interventions are not likely to affect the levels of the most toxic species generated through this process, and might consequently be less clinically effective.
Specifically, studies of the Aβ aggregation mechanism have revealed a multistep process that includes primary nucleation of monomers into aggregates, growth of aggregates by monomer addition and autocatalytic aggregate multiplication by secondary nucleation of monomers at the surfaces of existing fibrils (7) . Above a critical concentration of fibrils, this latter process becomes the dominant source of new low molecular weight Aβ oligomers. Secondary nucleation thereby connects the production of oligomers to the concentrations of both monomers and fibrils through a non-linear feedback network. There are two fundamental approaches to reduce the flux of oligomeric species: first by directly inhibiting the molecular reaction through which they form, and second by removal of the reactants, including the catalytic fibril surfaces. We present here a strategy based on a quantitative molecular analysis to assess the effects of four clinical stage antibodies, aducanumab (8) , gantenerumab (9, 10) , bapineuzumab (11) and solanezumab (12) , as murine analogs ch aducanumab, ch gantenerumab, 3D6 and m266, respectively, on both of these potential therapeutic modes of action. Clinical trials of Bapineuzumab and Solanezumab have been discontinued, while those of aducanumab and gantenerumab are still active.
First, we assessed the potency of the antibodies on the direct inhibition of secondary nucleation using chemical kinetics (5, 7, 13) . The action of an inhibitor is assessed through the global analysis of aggregation reaction time courses (5,6, Fig. S1 ), which are characterized by a lag-phase, a so-called growth phase and a final plateau. Crucially, all three underlying microscopic processes occur during all three phases, albeit at different rates, as governed by the rate constants and concentrations of reacting species at each point in time (14, 15) , implying that simple observations of the overall aggregation behavior do not readily allow the changes in molecular mechanisms to be determined.
In particular, both elongation and secondary nucleation exhibit their maximum rates during the macroscopic growth phase; the total nucleation rate is highest close to the mid-point (t0.5) of the reaction where both fibrils and monomers are present at approximately equal concentrations.
The aggregation of the 42-residue form of Aβ (Aβ42) was initiated by a temperature jump from 0 to 37°C, thus creating supersaturated solutions of Aβ42 monomers in the presence or absence of antibodies in pure buffer ( Fig. 1 , S2-S5) or in human cerebrospinal fluid (CSF, Fig. S6 , 16, 17) . For each dataset, recorded at constant Aβ42 concentration and increasing concentrations of each antibody, we performed a fit to the integrated rate law describing the Aβ42 aggregation process where one of the molecular rate constants, kn, k2 or k+ for primary nucleation, secondary nucleation and elongation, respectively, was allowed to vary upon addition of the antibody (16, Fig. 1 ).
Moreover, experiments were conducted in the presence of fixed low (Fig. S7 ,S8) or high ( Fig. 1, first column) concentrations of pre-formed seed-aggregates in the initial reactant solution, thereby bypassing primary or both primary and secondary nucleation to probe specifically the effects on secondary nucleation and/or elongation. All the experiments were run in a blinded manner using the four anti-Aβ antibodies as well as an isotype control antibody P1. 17 .
We found that ch aducanumab selectively and dramatically reduces the secondary nucleation rate of Aβ42 ( Fig. 1A) , lowering the effective rate constant for this process by ca. 40% even at the lowest concentrations of antibody tested (250 pM, Fig. S4 ). By contrast, the data show that m266 selectively inhibits primary nucleation (Fig. 1C ). For both of these antibodies, no changes are detected to the highly pre-seeded aggregation reaction when high concentrations of antibody are introduced into the reactions, highlighting that the growth of pre-existing aggregates is largely unchanged ( Fig. 1 ). Moreover, 3D6 and ch gantenerumab both act predominantly by reducing the growth of the fibrillar aggregates under both pre-seeded and unseeded reaction conditions ( Fig. 1B,   1D ). For comparison, the isotype control antibody has no detectable effect even at high concentration ( Fig. S3 ). In order to extend these findings to physiological conditions, we used CSF in the aggregation assay. In this case, Aβ42 displayed an extended lag phase consistent with earlier findings (Fig. S6 , ref. 17, 18) . However, each antibody was found to predominantly inhibit the same step as in buffer ( Fig. 1, S6 ,S7), with variations in the values of the rate constants reflecting the change of environment from buffer to CSF.
We next verified the reduction in oligomer production predicted to originate from inhibition of secondary nucleation by performing direct measurements of the oligomer concentrations. To this effect, we quantified the concentration of oligomers present at the half time of the aggregation reaction using MALDI mass spectrometry and size-exclusion chromatography (SEC), after the addition of a known amount of isotope standard ( 15 N-Aβ42) and proteolytic digestion (19; Fig. 2 ).
The results reveal that ch aducanumab causes a clear reduction of the free oligomer concentration, in direct agreement with the observed reduction in secondary nucleation, while a smaller reduction is observed with 3D6 and in particular with ch gantenerumab, neither of which significantly inhibits secondary nucleation. Interestingly, a fraction of Aβ42 elutes together with ch aducanumab in the void; given its low affinity of ch aducanumab for Aβ42 monomers this most likely represents bound oligomers ( Fig. S9 ). Such direct binding of oligomers could potentially prevent their further conversion to growth-competent fibrils, but could in turn increase their population, although the bound oligomers may be de-toxified by such capture. For m266 we observe a very large amount of Aβ42 eluting in early size exclusion chromatography fractions ( Fig. S10 ), consistent with the observation that this antibody binds with high affinity to the monomer (24) .
The specific inhibition of secondary nucleation (Fig. 1) , and the corresponding reduction in free oligomer concentration ( Fig. 2) , identified in the presence of ch aducanumab implies that this antibody's activity is likely to be driven predominantly by interactions with species unique to secondary nucleation, i.e. the fibril surface, rather than interactions with soluble species which are involved in both primary and secondary nucleation. To verify the molecular species on which this antibody acts, therefore, we performed experiments in which newly formed Aβ42 fibrils, produced in the presence or absence of ch aducanumab, were diluted and added to freshly prepared monomer solutions ( Fig. S11 ). We observed that pristine fibrils that had not been exposed to ch aducanumab at any stage enhance the process of secondary nucleation and increase the rate of aggregation, whereas pre-formed fibrils that had been generated in the presence of 0.1 molar equivalents of ch aducanumab accelerate aggregation to a significantly smaller extent. Kinetic analysis (Fig. S11) reveals a reduction of approximately ca. 33% in the apparent rate constant for secondary nucleation in this latter case, a value that is similar to that identified from the analysis in Fig. 1 
showing that a significant fraction of the inhibitory effect on secondary nucleation originates from interaction of the antibody with fibrillar aggregates.
In order to further investigate the origin of the kinetic inhibition and to assess additional modes of action through reduction in the concentrations of the reactants for secondary nucleation, we probed directly the stoichiometry and affinity of the interactions between each antibody and Aβ42 monomers and fibrils. These interactions were investigated by monitoring changes in the diffusion coefficients of the equilibrated species through microfluidic diffusional sizing (20,21; Fig. 3 ). The data reveal that ch aducanumab has a low affinity for Aβ42 monomers (pKD = -10 logKD = 10 logK = 5.04±0.08, K D =9±2 µM, the error given is the standard deviation), but a very high affinity for fibrils (pKD = 9.0±0.1, K D =1.0±0.2 nM). The affinity we obtain here in solution is a factor of 5 lower than for surface-immobilized fibrils (24) . These findings imply a remarkable specificity ratio of over four orders of magnitude for fibril binding over monomer binding, potentially a result of avidity effects since the epitope, residues 3-7, (24) is exposed in monomers as well as fibrils; this segment is relatively disordered and not included in the ssNMR structure of Aβ42 fibrils (22; Fig.   3B ). In addition, the diffusion data provide information on the stoichiometry of binding. We find one ch aducanumab molecule per ca. 5 Aβ42 monomers in the fibril (Fig 3C, S13) . Interestingly, the width of each antigen-binding region of an IgG is indeed similar to the summed pitch of 5 planes of an Aβ42 fibril (Fig. 3B ), and the measured value of the stoichiometry implies that fibrils can become fully coated with ch aducanumab along their entire length, which would effectively interfere with secondary nucleation at the fibril surface. The remarkable specificity of ch aducanumab in suppressing secondary nucleation with no observable effect on elongation ( Fig. 1 ) redirects a significant part of the reactive flux from secondary nucleation to elongation.
The microfluidic diffusional sizing measurements further reveal a moderate affinity of ch gantenerumab for Aβ42 monomers (pKD = 6.3±0.1, KD=485±100 nM) and a higher affinity for fibrils (pKD = 7.5±0.3, KD=30±15 nM). The stoichiometry of one ch gantenerumab per 43±4 monomers in the fibril, was obtained using short fibrils (50 nm, i.e. ca. 100 planes per filament), thus suggesting that ch gantenerumab binds favorably to fibrils ends, rationalizing the specific kinetic fingerprint of this antibody in inhibiting fibril growth ( Fig. 1 ). These findings are consistent with Aβ residues 18-27 forming an essential part of the epitope (9, 25) ; several side-chains of this segment are buried in the fibril core and only accessible at the fibril ends (22,23; Fig. 3B ). The affinities obtained here in solution are of a similar order of magnitude but generally lower than those reported for interactions with gantenerumab at surfaces (24) , an observation which can be typical of surface-based methods that can overestimate binding affinities, which could also be influenced by the labelling or differences between the human and mouse versions of this antibody. Next, for 3D6 we find a relatively high affinity for Aβ42 monomers (pKD = 7.4±0.1, KD=38±8 nM) and a very high affinity for fibrils (pKD = 9.57±0.36, KD = 0.27±0.20 nM) with a stoichiometry of 1 antibody per 47±10 monomers in the fibril. All kinetic data with 3D6 can be explained by a reduction of k+ ( Fig. 1C , S6C, S8E). Finally, for m266 we observe no measurable binding to fibrils but a very high affinity for monomers (pKD = 8.5±0.3, KD = 3±2 nM), which is consistent with suppression of primary nucleation ( Fig. 1 ) and the very large concentration of Aβ42 eluting in early fractions likely representing antibody-bound monomers (24, Fig. S10 ).
Taken together, the kinetic and binding data suggest that the antibodies studied here have dramatically different modes of action. In particular, the kinetic fingerprints shown in Fig 4a reveal that only ch aducanumab specifically reduces the rate of the secondary nucleation pathway. To verify this mode of action, we benchmarked the activity of ch aducanumab against the effect of a known and highly specific secondary nucleation inhibitor, the chaperone domain Brichos from pro-SPC (10) . The data shown in Fig 4a reveal that ch aducanumab has the same kinetic fingerprint as Brichos while the other antibodies exhibit a different type of behavior. To demonstrate the highly specific nature of the inhibition of secondary nucleation by ch aducanumab, we next investigated the combined effect of the antibodies together with the chaperone. Since the kinetic fingerprints show that both ch aducanumab and the chaperone inhibit secondary nucleation specifically, the analysis predicts that no effects on the aggregation kinetics will be observed upon the addition of ch aducanumab in the presence of excess Brichos. By contrast, since the kinetic fingerprints for gantenerumab and 3D6 show that these antibodies inhibit processes other than secondary nucleation, an additive inhibitory effect is expected even in the presence of excess chaperone. These predictions are verified by the data probing the aggregation process in the presence of each of the antibodies and Brichos (Fig 4b) , demonstrating the specific activity of ch aducanumab in inhibiting the secondary nucleation pathway.
In addition to direct inhibition of secondary nucleation, a second potential mechanism of action to reduce oligomer flux is the removal of the reactant species required for this process, monomers and fibrils. Monomer removal is likely to be challenging in vivo since it would require stoichiometric amounts of antibody to enter the brain, but crucially removal of the catalytic fibril surface is possible at sub-stoichiometric antibody concentrations. This latter process requires a significant fibril-bound antibody population; the binding analysis reveals that ch aducanumab has a KD for fibril around 1 nM, and is significantly more specific to aggregated species than the other clinical antibodies tested here ( Fig. 3N ). Indeed, calculating the fraction of fibrils that are antibody bound as a function of free antibody concentration predicts that ch aducanumab will be highly fibril bound even at low concentrations, whereas 3D6 in spite of its higher affinity, and especially ch gantenerumab, and due to its lower stoichiometry per fibril, require relatively higher concentrations of free antibody to achieve the same fraction of bound fibrils ( Fig. 3M ).
Our results demonstrate that kinetic fingerprints acquired in vitro ( Fig. 4 ) are able to reveal the strikingly varied mechanisms of action of clinical stage antibodies that have commonly been classified together as a single category of Aβ-targeting therapies. We illustrate the power of this approach by demonstrating that ch aducanumab is effective at both reducing the rates of secondary nucleation, leading to a decrease in the flux of oligomeric forms of Aβ, as well as binding amyloid fibrils, thus targeting them for removal, a unique mechanism of action that may help explain its reported clinical activity (8, 27) .
Supplementary Information is available for this paper. SL, TS, SD, CKX and GM analyzed the diffusion data. SL, MV, SC, TPJK, OH wrote the paper with input from all co-authors.
DISCLOSURES

DATA AVAILABILITY
The data that support the findings of this study are available from the corresponding author upon reasonable request. We note that at very high concentrations (>500 nM), which are unlikely to be realized in vivo, ch aducanumab accelerates the bulk Aβ42 aggregation process by increasing the primary nucleation rate. Indeed, the data at 250-1000 nM ch aducanumab are best fitted assuming that the effect on k2 is combined with an increase in kn (Fig. S4) . Interestingly, at high concentrations of each antibody, the ThT intensity is significantly reduced, which for m266 and 3D6, is found to be related to a significant concentration of Aβ1-42 remaining in solution (Fig. S5) , implying the possibility of monomer binding which we assess directly in solution ( Fig. 3) . Figure S4 . Effects of the antibodies on the rate constants. The rate constant values relative to Aβ42 alone are shown as a function of the antibody concentration for the case that produced the best fit to the data for each antibody (see Fig. 1 ). For ch aducanumab (A) we thus show the effect on the rate constant for secondary nucleation, k2, up to 125 nM antibody, and thereafter the effects in kn and k2. For m266 (B) we show the effect on the rate constant for primary nucleation, kn. For 3D6 (C) and ch gantenerumab (D) we show the effect on the elongation rate constant, k+. Figure S5 . Measurements of the amounts of Aβ42 monomers remaining in solution at the end of the aggregation reaction. We measured the Aβ1-42 monomers remaining in solution after reaching the ThT plateau in the presence of antibodies that cause a drop in final ThT intensity. Sample from multiple wells (300-400 µl) were collected after reaching the ThT plateau and fibrils were removed by centrifugation. A small sample (10 µl) from the top of the supernatant was analyzed using SDS PAGE (the standard, S, in panel C and B is at 10 kDa). Lane Aβ shows monomers before aggregation, the lane labeled 0 shows the remaining monomer at the plateau for Aβ1-42 alone. Lanes 1-5 correspond to 1:1 serial dilutions of antibody from 500 nM ( ch aducanumab, 3D6 and ch gantenerumab) or 1 µM (m266). Remaining Aβ1-42 monomers at the plateau are clearly detected with 1 µM, 500 nM and 250 nM m266, and with 500 nM and 250 nM 3D6. Faint Aβ1-42 bands are seen with 125 nM m266 and 125 nM 3D6. Thus, the reduced ThT intensity at the plateau intensity is, at least in part, due to less monomer being consumed in the reaction when high concentration of m266 or 3D6 are present. No Aβ1-42 monomer is detected by this method at the plateau in the presence of ch aducanumab or ch gantenerumab, indicating that the effect on the ThT plateau intensity is not due to less monomer being consumed in the reaction. Instead, it is likely an effect of these antibodies interfering with the ThT signal. All data were acquired using Aβ1-42 at 37 °C under quiescent conditions in 20 mM HEPES/NaOH, 140 mM NaCl, 1 mM CaCl2, pH 8.0 in PEGylated plates.
Figure S6. Effects of the antibodies on the aggregation kinetics of Aβ1-42 in CSF.
ThT fluorescence as a function of time for reactions starting from 6 µM Aβ1-42 in 66% CSF, 20 mM HEPES/NaOH, 140 mM NaCl, 1 mM CaCl2, pH 8.0 in the absence and presence of ch aducanumab (A), m266 (B), 3D6 (C) or ch gantenerumab (D). The colour codes for the antibody concentrations are given in nM in each panel. The left column shows data obtained in the presence of 30% preformed seeds, with linear fits, and the following three columns show nonseeded data fitted three times with the selective variation of one rate constant in each column. For ch aducanumab, the heavy seeded data rule out an effect on k+, and we can identify a reduction in k2 as the model which best fits the ch aducanumab data in CSF; this is verified using light seeding in CSF (Fig. S7) . Likewise, for m266 the heavy seeded data rule out an effect on k+, and we can identify a reduction in kn as the model which best fits the m266 data in CSF. For 3D6 as well as ch gantenerumab, the seeded data show an effect on k+, which indeed explains also the non-seeded data in CSF. Note that the x-axis covers 2.2, 6 or 8 h depending on the magnitude of the effect of each antibody. Example of a MALDI TOF-TOF spectra with HPLC separation before spotting for samples collected at the halftime of aggregation of Aβ1-42 in the presence of m266. In Fraction 9 there is so much 14N peptide that the signal from 15N is suppressed.
Figure S11. Effects of ch aducanumab in light seeded (2%) aggregation kinetics of Aβ1-42.
ThT fluorescence as a function of time for reactions starting from 3 μM Aβ1-42 in the absence (grey) or presence of 60 nM preformed seed fibrils in 20 mM HEPES/NaOH, 140 mM NaCl, 1 mM CaCl2, pH 8.0. The seeds were made in the absence (black) or presence of ch aducanumab (green). The total concentration of ch aducanumab in the samples for the data shown in green was 6 nM. The fits assume a constant value of k+ and curve-specific values of k2. The relative values of k2 obtained are 1.0 (grey), 1.0 (black) and 0.67 (green). Thus, forming the seeds in the presence of ch aducanumab leads to a 33% reduction in apparent k2, very similar to what we observed with 6 nM ch aducanumab in the non-seeded data ( Fig S4) . We conclude that a significant fraction of the inhibitory effect on secondary nucleation originates from interaction of the antibody with fibrillar aggregates. 
Online Methods
Chemicals and solutions
All chemicals were of analytical grade. All buffers were filtered (200 nm) and extensively degassed before use. Thioflavin T (ThT) was from CalBiochem and was prepared as a stock solution in water, which was filtered through 200 nm filter and the concentration determined using absorbance. CSF was collected from de-identified healthy donors, pooled and frozen as multiple identical aliquots.
Expression of Aβ1-42 peptide
Due to the requirement of an ATG start codon yielding an N-terminal Met residue, Aβ1-42 cannot be expressed "as is" and requires a fusion tag. We employed the self-cleavable tag nPro in the form of its EDDIE mutant (28). EDDIE-Aβ1-42 with the amino acid sequence MELNHFELLYKTSKQKPVGVEEPVYDTAGRPLFGNPSEVHPQSTLKLPHDRGEDDIETT LRDLPRKGDCRSGNHLGPVSGIYIKPGPVYYQDYTGPVYHRAPLEFFDETQFEETTKRIG RVTGSDGKLYHIYVEVDGEILLKQAKRGTPRTLKWTRNTTNCPLWVTSCDAEFRHDSG YEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA, with the Aβ1-42 sequence underlined, was expressed from a Pet3a plasmid (purchased from Genscript, Piscataway, New Jersey) in E. coli BL21 DE3 PlysS star in overnight express medium (2.5 mM Na2HPO4, 2.5 mM KH2PO4, 12 mM (NH4)2SO4, 1 mM MgSO4, 0.1 g/L glucose, 0.4 g/L lactose, 1 g/L glycerol, 10 g/L NaCl, 10 g/L tryptone, 5 g/L Bacto yeast extract, 50 mg/L ampicillin, 30 mg/L chloramphenicol). 
Purification of Aβ1-42 peptide
Expression and purification of Aβ(M1-42) peptide
Aβ(M1-42) was expressed from a PetSac (derivative of Pet3a) plasmid in E. coli BL21 DE3 PlysS star in M9 minimal medium with 15 NH4Cl as the only nitrogen source and purified essentially as described (7, 29) : Cell pellet from 4 L culture was sonicated in 80 mL 10 mM Tris/HCl, 1 mM EDTA, pH 8.5 (buffer A) using a sonicator tip (half horn, 50% duty cycle, maximum output, 30-90 s). This step was performed in a glass beaker surrounded by an ice-water slurry. Inclusion bodies were isolated by centrifugation at 4°C and 18,000 x g for 10 min. Two more rounds of sonication and centrifugation were performed. The inclusion bodies were dissolved in 80 mL buffer A containing 8 M urea and diluted 4-fold in buffer A. 40 mL DEAE cellulose (Whatman DE23, equilibrated in buffer A with 2 M urea) was added, and the slurry was left on ice for 30 min (with periodic stirring using a glass rod). The solution was removed, and the resin washed with buffer A in a Büchner funnel on a vacuum flask, followed by two washes with 100 mL buffer A and elution with 8 x 30 ml buffer A containing 75 mM NaCl. The ion exchange purification was performed in batch mode to avoid concentrating Aβ peptide on the resin. The eluted fractions were examined using SDS PAGE with Coomassie staining. Fractions dominated by Aβ42 monomer were lyophilized, dissolved in 10 mL 6 M GuHCl and isolated from residual E. coli proteins, aggregates and small molecule contaminants using size exclusion chromatography on a Superdex 75 26/600 column at 4 °C. The eluted fractions were examined using UV absorbance, agarose gel electrophoresis and SDS PAGE with Coomassie staining. Fractions corresponding to the center of the Aβ(M1-42) monomer peak were pooled lyophilized, dissolved in 10 mL 6 M GuHCl, 20 mM sodium phosphate, pH 8.5 and subjected to a second round of size exclusion chromatography on a Superdex 75 26/600 column at 4°C. Fractions corresponding to the centre of the Aβ42 monomer peak were pooled, aliquoted and lyophilized.
Generation ad purification of anti-Aβ antibodies
Murine chimeric IgG2a/kappa versions of aducanumab ( ch aducanumab), gantenerumab ( ch gantenerumab), bapineuzumab (3D6) and solanezumab (m266) were generated as described (24, 30) . The variable domain amino acid sequences of bapineuzumab (31) and gantenerumab (9) were selected based on publicly available sequence information and used to generate murine chimeric analogs. The resultant antibodies contain the variable heavy (VH) and variable light (VL) domains of the specific antibody and murine IgG2a/kappa constant heavy and constant light domains. An mIgG2a isotype control antibody P1.17 was generated from a murine myeloma cell line (ATCC TIB-10). All antibodies were expressed in CHO cells and purified by protein-A-affinity followed by ion-exchange chromatography. Purified antibodies were frozen as multiple identical aliquots.
Prior to setting up the kinetics experiment, these aliquots were further purified using size exclusion chromatography on a 10x300 mm Superdex 200 column eluted in 20 mM HEPES/NaOH, 140 mM
Blinding of antibodies
The studies were run blinded such that several antibodies that were studied in parallel and their identities were not known to the person setting up the experiments and analyzing the data. In the experiments with Aβ1-42 at physiological salt buffer and in CSF there were four antibodies (isotype control, ch aducanumab, 3D6, ch gantenerumab). After un-blinding, the effect of m266 was investigated in physiological salt buffer and CSF. 
Seeded aggregation kinetics
The seed fibrils were prepared from 5 µM Aβ1-42 monomer solutions (in 20 mM HEPES/NaOH, 1 mM CaCl2, 140 mM NaCl, pH 8.0, 10 µM ThT, as above) by incubation at 37°C under quiescent conditions in a plate reader monitoring ThT fluorescence and collecting the fibrils when the fluorescence reached the post-transition plateau. Fresh Aβ1-42 monomer solutions were prepared as above. The seed fibrils were diluted to two times the desired final concentration and mixed with equal volume of fresh monomer solution to achieve a final seed concentration of either 30% or 2% of monomer concentration equivalent. Seed-free samples were made for comparison; the monomer solution was mixed with equivalent volume of buffer. Kinetic measurements were made as described above (1.7).
Aggregation kinetics in the presence of Brichos
The Brichos domains from pro-SPC was expressed and purified as previously described (5, 31, 32) . Aggregation kinetics were followed as above under quiescent conditions in 20 mM HEPES/NaOH, 1 mM CaCl2, 140 mM NaCl, pH 8.0, 10 µM ThT, in PEGylated plates, for reactions containing 3 µM Aβ1-42 monomer, or 3 µM Aβ1-42 monomer plus 3 µM Brichos, or 3 µM Aβ1-42 monomer plus 3 µM Brichos plus 250 nM of one of the following antibodies: ch aducanumab, m266, 3D6 or ch gantenerumab.
SDS PAGE analysis of monomer concentration at the end of the reaction
This experiment was aimed at measuring if there is any remaining Aβ1-42 monomer at the ThT plateau in the absence and presence of the antibodies. Samples were collected at the end of the aggregation kinetics, fibrils were removed by centrifugation at 31,500 x g for 2 minutes in a benchtop centrifuge (Hettich Zentrifugen MIKRO 220R) and the supernatant was mixed 1:1 with SDS Loading buffer and analyzed using SDS PAGE on 4-20% polyacrylamide gradient gels (Novex) with a Tris/Bis-Tris Buffer system containing 0.1% SDS. The gels were stained with Coomassie Blue and the intensity of gel bands was compared to that of a monomer standard.
Kinetic analysis
The aggregation data in the absence and presence of different concentrations of antibodies were normalized and fitted using the Amylofit on-line platform (16) [7] In these relations, [m]0 is the initial monomer concentration, [P]0 is aggregate number at the start of the reaction, [P]∞ is the aggregate number at equilibrium, that is, after reaction completion, [M]0 is the mass concentration of fibrils at the start of the reaction and [M]∞ is the mass concentration of fibrils at equilibrium. kn, k2, k+ are the rate constants for primary nucleation, secondary nucleation and elongation respectively. KM is the saturation constant for secondary nucleation and nc and n2 are the monomer scalings of primary and secondary nucleation, respectively. The values nc = 0.0001, and n2 = 2 were used for fitting of all aggregation kinetics in 20 mM HEPES/NaOH, 1 mM CaCl2, 140 mM NaCl, pH 8 (18) .
Microscopic mechanism of inhibition. The action of an inhibitor can be assessed through the analysis of macroscopic aggregation curves (5, 6) . Inhibition of primary nucleation (rate constant kn) causes a lag-phase prolongation with no effect on the transition steepness, thereby delaying the generation of oligomeric species through secondary nucleation (Fig. S1B,E) . This type of inhibition requires compounds that bind Aβ monomers, nuclei or other oligomers (6, (34) (35) (36) . By contrast, inhibition of secondary nucleation (with rate constant k2) causes little lag-phase extension but a reduction of the transition slope (Fig. S1A,D) . This route for therapeutic intervention may significantly reduce toxicity (5) , and requires inhibitors that block the catalytic surface of fibrils, or bind to on-pathway oligomers to prevent their conversion to fibrils (5, 6, 34, 37, 38) . Finally, inhibition of elongation (with rate constant k+) causes both a lag-phase extension and a reduction in transition slope (39) , an effect that may increase toxicity over time (5, Fig. S1C,F) . When the ends of fibrils are blocked, a larger fraction of the monomers bind to their sides, where secondary nucleation and oligomer generation is catalyzed.
Oligomer size distribution and concentration
The concentration of oligomers and their size distribution was estimated at t1/2, the point in time where half the monomers were converted to fibrils (14, 15, 19) . Aβ1-42 monomers were isolated by gel filtration in 20 mM HEPES/NaOH, 1 mM CaCl2, pH 8.0, followed by addition of 140 mM NaCl from a concentrated stock. Solutions containing 5 µM monomer and 100 nM antibody (isotype control, ch aducanumab, ch gantenerumab, m266 or 3D6) were prepared in the same buffer where CP is the total concentration of labelled protein (monomer or antibody), CL is the total concentration of unlabelled protein (the ligand), fP and fPL are the fractions of free labelled protein and bound labelled protein, respectively, in the diffused half of the channel, and n is the stoichiometry of the interaction, such that nCL is the total concentration of binding sites on the unlabelled component. For data with Alexa-647-labelled Aβ42 monomer, n was fixed to 2 (two monomer-binding sites per antibody), while fP, fPL and KD were fitted parameters. For data with Alexa-647-labelled antibodies, n, fP, fPL and KD were fitted parameters.
Based on the ratio of fN and fD, the instrument reports an apparent hydrodynamic radius of the fluorescently labelled species, the principles of which have been described previously (20, 21) .
However, the measured radius is not linearly related to the concentrations of free and bound labelled substrate.
Bayesian inference details
The Bayesian inference analysis method utilizes Bayes' theorem, and allows the determination of the probability distributions of unknown parameters, given the observed data, by the following equation:
where ( | ) is known as the posterior, ( ) as the prior, and ( | ) as the likelihood. The prior probability distribution is an expression of our information about the system before we acquire any measurement data. For and , we assume the prior is flat in linear space, whereas for the and, in the case of the fibrils, , a prior that is flat in logarithmic space is more appropriate, to reflect the scale invariance of the problem.
We assume our experimental measurement data to be normally distributed about the true value; our likelihood function is therefore a Gaussian, centered on the theoretical measurement value.
( | ) ∝ exp [− 1 2 2 ∑ ( − ( , , , , , , , )) 2 =1 ] [9] where is defined as above, with or without the n dependence, as determined by whether the A is monomeric or fibrillar, , and , are the total concentrations labelled and unlabeled species, respectively, in the i th measurement, with both having an index i as we combine all data sets for each combination of labeled and unlabeled species. is the fraction of diffused labelled component in the i th measurement. In order to define an appropriate standard deviation, , for each dataset, we calculate the standard deviations of repeats of each measurement, and use the maximum of these values as a global standard deviation for that dataset.
Fraction bound labeled species
After fitting, the fractional saturation of the labelled species, Q, was calculated from each data point, using the fitted values of fP and fPL as follows = − − [10] and plotted versus free ligand concentration, which was calculated at each total concentration of added ligand, CL, as follows [ ] = 0.5( − − ) + √(0.25( − − ) 2 + ) [11] using in the case of Alexa-647-Aβ42 interacting with antibody the fitted value of KD and the fixed values of n and CP, and in the case of Alexa-647-antibody interaction with fibrils, the fitted values of n and KD and the fixed value of CP.
Fraction of fibrils with at least one antibody bound
The fraction of fibrils with at least one antibody bound, fB, was calculated assuming no cooperativity, i.e. the affinity for each site is the same irrespective of whether the other sites on the same fibril are occupied or not. The probability of a given site to be occupied is + , where
Af is the concentration of free antibody. The number of species bound per fibril gives a binomial distribution, thus the fraction of fibrils with one or more antibodies bound is given by
where s is the number of antibody binding sites on the fibril and we used the fact that the fraction of fibrils that have more than one antibody bound is equivalent to 1 minus the fraction that has no antibodies bound. The values used to calculate the curves shown in Figure 4L assume short fibrils of 400 monomers (50 nm fibrils, two filaments, two monomers per plane in each filament 
